Adam Bruce comes with a background in product innovation and entrepreneurship. He’s been instrumental in establishing TikoMed, a company with now two projects in Phase 2 clinical development for neurology and cell therapy. During his time at TikoMed he has served in positions as CEO, Chairman, Business Development, and project VP. Over the years Adam has provided advice on financing and strategic development in various constellations for life science and med-tech companies. Adam holds a business degree from Lund University.

Professor Emeritus
Lund University
University of Geneva

Claes Wollheim is a qualified Swedish physician and an international authority on beta-cell biology and diabetes research. He has dedicated almost five decades to preclinical diabetes research, focusing on the hormones secreted from the islets of Langerhans changing the view of diabetes from a disease dominated by insulin resistance to one in which beta-cell dysfunction is also central. He received numerous scientific distinctions, including the Claude Bernard Prize of the European Association for the Study of Diabetes (EASD), honorary doctor degrees (Doctor Honoris Causa) of Semmelweis University, Budapest and Lund University as well as an elected member of the Swiss Academia of Medical Sciences and Academia Europaea.

Jan Alenfall earned his doctorate in tumor pharmacology and biology from Lund University in 1995. With over 25 years of pharmaceutical R&D experience, he has authored more than 20 scientific papers and holds multiple pending patents. Early in his career, he focused on innovative treatments for immunological disorders and cancer, working on clinical trials in immunology and oncology at Pharmacia & Upjohn.

In 2013, he became Managing Director of Follicum AB, which developed peptide-based drugs for various indications, including diabetes, before it was transitioned to Coegin Pharma. Jan specializes in early-stage pharmaceutical development, business planning, risk assessment, and the design and execution of preclinical and clinical studies, demonstrating a strong research focus and goal-driven leadership.

Currently, Jan is the CEO of Callipa AB, his consulting company, and Edvince AB, a company involved in treatment for stroke.

Per Aniansson brings over 25 years of experience in life sciences and investments, from early-stage start-ups to large public companies. He holds an MSc in Engineering Physics from Chalmers University of Technology and an MBA from INSEAD.

Per has held leadership roles including Investment Director and CFO at Karolinska Development and has been a key figure in several venture capital and investment firms such as Fouriertransform, InnovationsKapital, Siemens, and Industrivärden.

His early career includes working with Accenture and Arthur D. Little, where he focused primarily on the Pharma and Medtech sectors. He has hands-on entrepreneurial experience as CEO of two UK-based medtech companies, and today Per serves as Chairman of the Board at the synthetic biotech company Colorifix and the SaaS company Turnpike. He is also a board member of PharmNovo, AAC Clyde Space, Star Syringe, Sinsa Labs, and the Cure Cancer Foundation.

Helen Petersson works as an Investment Manager at Almi Invest South. She focuses on Life Science and is responsible for the entire investment process, which means finding, investing in and developing innovative companies with growth potential and implement an exit strategy from the holding through a listing or strategic sale. Currently, she is the Investment Manager of 6 of Almi Invest South’s portfolio companies and a board member of 5 companies.

She earned a PhD in Tumor Immunology and began her career as a translational cancer researcher. Before joining Almi Invest, Helen was a Senior Project Manager at the Danish-Swedish life science cluster organization Medicon Valley Alliance.

Board Member

Claes Wollheim is a qualified Swedish physician and an international authority on beta-cell biology and diabetes research. He has dedicated almost five decades to preclinical diabetes research, focusing on the hormones secreted from the islets of Langerhans changing the view of diabetes from a disease dominated by insulin resistance to one in which beta-cell dysfunction is also central. He received numerous scientific distinctions, including the Claude Bernard Prize of the European Association for the Study of Diabetes (EASD), honorary doctor degrees (Doctor Honoris Causa) of Semmelweis University, Budapest and Lund University as well as an elected member of the Swiss Academia of Medical Sciences and Academia Europaea.

Ulrich S. Koch worked for 35+ years in the pharmaceutical industry at Schering and Bayer having been based in Germany, in the United Kingdom, and in the USA. During this time he was responsible for Strategic Marketing, Licensing, and Business Development, managed international teams, negotiated several important Licensing and M&A deals, and coordinated the respective implementation of such partnerships. Currently, Ulrich Koch works as Senior Transaction Manager for the New York-based investment firm Ferghana Partners and provides additional partnering services as head of Venice Pharma Consultancy. For 20+ years he is also a board member, speaker, and trainer within the European IPLS network (International Partnering in Life Science Society). Ulrich is an economist by training.

Professor of Pharmacology
Ben and Wanda Hildyard Chair
Mitochondrial and Metabolic Diseases
University of California, San Diego
Expert in mitochondria, inflammation, and metabolic diseases.

Professor of Medicine and Metabolism
University of Washington
Clinical leadership positions in numerous T2D trials including the Diabetes Prevention Program, Diabetes Prevention Program Outcomes Study (DDP / DPPOS), Look AHEAD, Restoring Insulin Secretion Study (RISE) and Glycemia Reduction Approaches in Diabetes (GRADE).

Senior Vice President
Antibody Discovery, Alloy Therapeutics (US)
Former Director, Antibody Technology, Novo Nordisk (DK)